featured-image

Olemedia/E+ via Getty Images Obesity drug developer BioAge Labs ( BIOA ) has filed regulatory filings as part of its U.S. IPO.

It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at the midpoint..



Back to Health Page